The PKC-Diabetic Retinopathy Study (PKC-DRS) reported that ruboxistaurin was associated with a reduced incidence of moderate visual loss (doubling of the visual angle) [100]. This evidence concerns the gene PRRT2 and diabetic retinopathy.